Objective: The objective of this study was to prospectively evaluate the clinical features of chemotherapy-induced oral mucositis (CIOM) in adult patients with acute leukemia and the aggravating factors for such symptoms. Subjects: Thirty-seven prospective patients aged ≥19 years with acute leukemia undergoing chemotherapy were enrolled. Oral and clinical investigations were performed at baseline and on Day 14 after starting chemotherapy. The presence and severity of cancer-induced oral mucositis were demonstrated using the World Health Organization (WHO) scoring system.
| INTRODUCTION
Leukemia is a kind of hematological cancer that is caused by an overproduction of white blood cell (WBC)-forming tissues resulting in a marked increase in circulating immature or abnormal WBCs (Shysh et al., 2017) . Leukemia is an uncommon disease, and the crude incidence rate per 100,000 was 6.4 in a Korean population (Jung, Won, Kong, Lee, & The Community of Population-Based Regional Cancer, 2018) . As the number of abnormal WBCs in acute leukemia increases faster than that in chronic leukemia, acute leukemia can be more deleterious (Belson, Kingsley, & Holmes, 2007) . The 2016 revision to the World Health Organization (WHO) classification of acute leukemia includes two main subtypes, namely, acute lymphoid leukemia (ALL) and acute myeloid leukemia (AML), according to their prognostic, morphological, immunophenotypic, genetic, and clinical traits (Arber et al., 2016) . AML is the commonest type of acute leukemia in adults (Yamamoto & Goodman, 2008) , whereas ALL occurs more frequently than AML in childhood and rarely occurs in adults (Belson, Kingsley, & Holmes, 2007; Gurney, Severson, Davis, & Robison, 1995; Shysh et al., 2017) . Thus, oral mucositis in adult patients with AML has not yet been fully assessed.
Chemotherapy involves the use of chemicals or drugs that destroy or prevent the reproduction of cancer cells in the leukemia patients. Approximately 80% of newly diagnosed patients with AML are treated with cytarabine, anthracyclines, such as daunorubicin or idarubicin, and cladribine (Buchner et al., 2003; Ohno et al., 1993; Rashidi, Walter, Tallman, Appelbaum, & DiPersio, 2016) . Clinically, patients under the age of 60 often receive intensive chemotherapy, and induction often involves treatment with two or more of the chemotherapeutic drugs. The adverse effects of chemotherapy are related to their cytotoxic activities against noncancerous cells of the body, resulting in undesirable anatomical and functional conditions such as dysphagia, vomiting, diarrhea, malnutrition, arthralgia, hemorrhage, anemia, and myelosuppression .
The oral cavity is also affected as a result of local and/or systemic side effects of chemotherapy, whereby oral lesions are called chemotherapy-induced oral mucositis (CIOM; Chen et al., 2011) . Oral mucositis is inflammation of the oral mucosa, occurring in 20-40% of patients receiving conventional chemotherapy (Lionel, Christophe, Marc, & Jean-Luc, 2006; Naidu et al., 2004; Scully, Sonis, & Diz, 2006) . Chemotherapy causes inflammation and ulceration through tissue damage resulting from a sequence of chemical, metabolic, and biological events that occur in several stages (Lopez-Castano, Onate-Sanchez, Roldan-Chicano, & Cabrerizo-Merino, 2005) . Thus, CIOM usually begins within the first week after the initiation of treatment and peaks in the second week (Lionel et al., 2006; Naidu et al., 2004; Scully et al., 2006) . Oral health plays an important role in the quality and life expectancy of an individual. However, the incidence and clinical characteristics of CIOM in patients with acute leukemia are still lacking.
Some patients with acute leukemia may receive allogeneic hematopoietic stem cell transplantation (HSCT), which involves profound immunosuppression and various related complications. The incidence of oral mucositis among patients receiving HSCT is reportedly up to 70% (Vagliano et al., 2011) , which is much higher than in patients who receive conventional chemotherapy. Oral mucosal disruption caused by CIOM can be fatal to patients because it provides a major route for the entry of pathological microorganisms, leading to various infections including fatal septicemia (Ruescher, Sodeifi, Scrivani, Kaban, & Sonis, 1998) . A significant percentage of oral lesions that are caused by anticancer treatments may be reversible, whereas little is known about how HSCT affects CIOM in patients with acute leukemia.
The aim of the current study was to prospectively determine the clinical features of CIOM in adult patients with acute leukemia and to compare their oral signs and symptoms between the two subgroups, ALL and AML. Additionally, we also aimed to determine the risk factors that aggravate the severity of CIOM. That is, we evaluated whether clinical factors such as location of the oral lesion, the number of lesions, subtype of acute leukemia, and treatment with HSCT affect the development and severity of CIOM in patients with acute leukemia. The understanding of specific oral manifestations in adult patients with leukemia following chemotherapy can facilitate the perdition of novel treatment and result in the ability to correlate causative factors to the severity of CIOM.
| MATERIALS AND METHODS

| Patients and study design
We performed a prospective, observational clinical study on adult population of patients with acute leukemia, comprising both ALL and AML forms. The diagnosis of acute leukemia subtypes ALL and AML was based on the 2016 WHO criteria (Barbui et al., 2018) . Medical records of each participant were reviewed at baseline, and their demographic and clinical characteristics such as age, sex, subtype of acute leukemia, and treatment with HSCT were investigated.
The inclusion criteria for the study were as follows: (a) age ≥ 19 years, (b) diagnosed with an acute leukemia and admitted for intensive chemotherapy, (c) did not have any oral lesions at baseline, and 
| Intensive chemotherapy regimens
Patients with AML or ALL were given standard intensive chemotherapy for curative intent after clinical judgement that they would be able to tolerate high-dose chemotherapy. For patients with AML, conventional 3 + 7 intensive chemotherapy (12 mgÁm −2 Áday −1 of idarubicin or 60-90 mgÁm −2 Áday −1 of daunorubicin for three consecutive days plus 100 mgÁm −2 Áday −1 of continuous cytarabine infusion for 7 days) was conducted for remission induction and either high-dose (3 gÁm −2 Áday −1 for Days 1, 3, and 5) or intermediate-dose (2 gÁm −2 Áday −1 for Days 1, 3, and 5) cytarabine was administered as consolidative chemotherapy. Patients with ALL received multiagent combination chemotherapy, according to either vincrisintine, prednisolone, daunorubicin, and L-asparaginase protocol (Park et al., 2003) or hyper-cyclophosphamide, vincristine, adriamycin, and dexamethasone alternating with high-dose methotrexate and cytarabine regimen (Thomas et al., 2004) . All ALL patients received appropriate central nervous system prophylaxis using intrathecal chemotherapy with methotrexate with or without cytarabine and hydrocortisone. ALL patients who had positive result for the breakpoint cluster region-proto-oncogene tyrosineprotein kinase rearrangement according to fluorescence in situ hybridization or polymerase chain reaction test, 600 mgÁday −1 of imatinib mesylate was added on the multiagent chemotherapy. (Lalla, Sonis, & Peterson, 2008) . The WHO score ranges from 0 to 4 points (Grades 0 to 4), with higher scores indicating greater severity of the CIOM status. This scale is a simple and easy-to-use measure that is appropriate for clinical applications.
| Measurement of CIOM
For patients with more than one lesion in the mouth, the most severe site was investigated. Two clinicians with at least 10 years of experience in the field, and who were blinded to the patients' medical information, performed the oral examination and visual analyses of the CIOM. This scale has been validated with highinterobserver reproducibility.
| Subjective discomfort in patients
On Day 14, all patients reported their subjective discomfort using the oral mucositis daily questionnaire (OMDQ; Stiff et al., 2006) . This questionnaire was designed to score the degree of discomfort felt by the patient during the preceding 24 hr. Of the total of 10 questions, two questions related to diarrhea were excluded leaving only eight questions to be answered by the patients in the present study.
The OMDQ sought information on the degree of subjective discomfort for the following two factors on a scale of 0 to 10: (a) overall 
| Statistical analysis
We obtained the absolute and percentage distributions of all nominal and categorical variables, as well as means and standard deviations, and performed descriptive data analysis. Results of ALL and AML patients were compared using the Mann-Whitney U test. The 
| RESULTS
| Patient enrollment and treatment
Patients were enrolled between July 2016 and May 2017 at Seoul National University Dental Hospital. Initially, 43 participants with acute leukemia were recruited. However, six were subsequently excluded, three patients on the basis of insufficient data, and three other patients because they had an unspecific subtype of acute leukemia ( Figure 1 ). Thus, 37 adult patients (52.38 ± 14.48 years, 18 males and 19 females) were finally included and evaluated. Of this cohort of patients, 32 had AML (53.56 ± 13.82 years) and five had ALL (44.80 ± 17.98 years). Overall, the male-to-female ratio of adult patients with acute leukemia was 0.95:1, and those of the various subtypes were 1.33:1 and 0.25:1 for AML and ALL, respectively. Overall, the maleto-female ratio is similar to that of the whole Korean population, which has been reported as 1.33:1 (Jung et al., 2018) .
Our results for adults aged 19 years or older show that the number of AML patients is 6.4 times more than that of ALL patients. It has been reported that the incidence of AML increases with age, from 1.3 cases per 100,000 population in patients less than 65 years old to 12.2 cases per 100,000 population in those over 65 years (Siegel, Miller, & Jemal, 2015) . Clinical demographics and characteristics of the enrolled patients are summarized in Table 1 . Table 1 also shows the mean and standard deviation of hematological factors. Lymphocyte level was significantly lower in AML, whereas ALC and CRP levels were significantly higher in AML (all p < .05).
| Hematological factors
Other hematological factors showed no significant differences. The reference normal ranges of each variable are as follows: WBC: 4,000-10,000/μl, lymphocytes: 15-52%, ALC: 1.0-5.1/μl, absolute neutrophil count: 2.0-8.0/μl, and CRP: 0-10 mgÁL −1 . Grade 3 or Grade 4. In general, CIOM is typically less severe and usually lasts for less than 2 weeks (Georgiou, Patapatiou, Domoxoudis, Pistevou-Gompaki, & Papanikolaou, 2012) . The incidence of CIOM was found to be 21.9% in the AML, and 20.0% in the ALL group. The numbers of CIOM, their distribution in the oral cavity, and the severity of CIOM were not significantly different between the two subgroups.
| Incidence, location, and the severity of CIOM
Among the 32 AML patients, six (18.0%) patients received HSCT, and CIOM was observed in half of them. The commonest site of CIOM was the ventral tongue (n = 4, 10.8%), followed by the buccal mucosa (n = 3, 8.1%), soft palate (n = 3, 8.1%), and gingiva (n = 1, 2.7%). When the data were divided according to the subtype, only one case in which the gingiva was affected was observed in ALL patients. Among the 32 AML patients, CIOM was observed on the ventral tongue (n = 4, 12.5%), followed by the buccal mucosa (n = 3, 9.4%) and soft palate (n = 3, 9.4%). CIOM was not observed in other parts of the mouth with the exception of the aforementioned four sites. The severity of CIOMs was estimated according to the WHO scoring system, and it was not significantly different between the AML and ALL groups. Table 3 shows the subjective complaints of oral pain or limitation of function using the OMDQ. When data were analyzed for the whole cohort of acute leukemia patients, a noticeably higher score was found for overall health status (4.97 ± 3.57) compared with that for overall mouth and throat soreness (1.88 ± 3.11). Upon investigating the degree of discomfort in daily activity, the highest value was found when eating (0.72 ± 1.34), followed by drinking (0.48 ± 1.16), swallowing (0.48 ± 1.01), sleeping (0.48 ± 0.92), and talking (0.24 ± 0.66).
| Subjective complaints of the patients
When the data were divided into two subtypes of disease, AML and ALL, the subjective discomfort of swallowing, drinking, and sleeping was significantly higher in patients with AML than in those with ALL (all p < .05). In both the AML and ALL groups, the score of overall health status was higher than that of overall mouth and throat soreness. Among the factors related to daily activities, difficulty in eating was the highest in both subgroups. However, the second highest score was different between the two subgroups; drinking was the second highest rate in AML, whereas none of the patients felt discomfort during daily activities such as swallowing, drinking, talking, and sleeping. However, some patients with ALL reported having difficulty eating. 
| Factors associated with severity of CIOM
| Correlations with CIOM severity
| DISCUSSION
A number of hematological malignancies including acute leukemia have manifestations in the oral cavity (Porter, Mercadente, & Fedele, 2018) . In a previous retrospective study, the most common oral manifestations of leukemia reported included gingival bleeding (43.2% in AML; 28.6% in ALL), followed by oral ulceration and gingival enlargement (Hou, Huang, & Tsai, 1997) . Gingival swelling has always been an early oral sign of an underlying leukemia (Lim & Kim, 2014) . For systemic symptoms, patients with acute leukemia frequently have fever (92.2%), followed by fatigue, weakness, and a feeling of helplessness (Hou et al., 1997) . Although oral mucositis is one of the commonest side effects when cancer patients experience chemotherapy, there have been few previous studies on CIOM in adult patients with acute leukemia (Dreizen, McCredie, & Keating, 1981; Rimulo, Ferreira, Abreu, Aguirre-Neto, & Paiva, 2011) . This may be because the prevalence of acute leukemia is low, and the disease is rare in adults compared with children. When acute leukemia is left untreated or misdiagnosed, the condition becomes rapidly fatal, within 1 year, in a majority of patients due to severe infection, hemorrhage, gingival, and gastrointestinal bleeding (Estey & Dohner, 2006) . Thus, clinicians should be aware of these systemic and oral manifestations of the patients. As far as we know, this is the first study to prospectively investigate the factors that influence the severity of CIOM incidence and symptoms in these patients.
Mucositis is the commonest oral complication among patients receiving chemotherapy (Sonis, 2004) . In the present study, the incidence rate was 21.6%, which increased to 50.0% in patients treated with a combination of intensive chemotherapy and HSCT. Oral mucositis, which is directly attributable to antileukemia chemotherapy, has been shown to occur in 20-40% of patients receiving such chemotherapeutic treatment (Figliolia et al., 2008; Scully et al., 2006) . Furthermore, mucositis is not only the commonest symptom of HSCT but it is also the most distressing complication, and about 30-50% of patients with HSCT complain that mucositis is the most toxic to them (Bellm, Epstein, Rose-Ped, Martin, & Fuchs, 2000) . In Korea, HSCT procedure was first performed in patients in 1983, and transplants have increased rapidly over the past 35 years (Cho, Lee, & Lee, 2018) .
The incidence of oral mucositis in patients receiving HSCT has also been reported to be 100% (Vokurka, Steinerova, Karas, & Koza, 2009 ), whereas the incidence has not yet been investigated in Korean patients who received HSCT. The relationship between HSCT and oral mucositis in adult patients with acute leukemia was first investigated in Korea, and our prospective study could provide the prevalence and clinical characteristics. In our results of linear regression analysis, HSCT certainly increased the severity of CIOM, but not with the subtype of leukemia, age, and gender. Oral mucositis after HSCT can also be a predictor of gastrointestinal toxicity and the onset of hepatic disease (Rapoport et al., 1999; Wingard et al., 1991) . To achieve much progress, more studies need to be conducted to alleviate the overall burden and severity of oral mucositis in patients with acute leukemia receiving HSCT.
In general, CIOM starts with the initial injury to cells by chemotherapy either as a direct DNA damage or as an indirect through the action of reactive oxygen species. Chemotherapy may be reflected on directly toxic to the oral cavity, as it performed by killing cells having high-mitotic activity, such as the cells that make up the oral mucosa (Velten, Zandonade, & Monteiro de Barros Miotto, M. H., 2017) . In our study, five out of eight patients were classified WHO Grade 2 with ulceration. A series of antioxidant and detoxifying enzyme and redoxsensitive transcription factor activations affect the submucosa layer and basal epithelium, leading to tissue damage (Georgiou, Patapatiou, Domoxoudis, Pistevou-Gompaki, & Papanikolaou, 2012; McKenna, 2000) . At its beginning stages or in its mildest form, in contrast, many patients have the more classic and severe form of mucositis that is usually accompanied by ulcerative lesions. Furthermore, development of ulcerative lesions is related with pain and inability to allow ordinary foods (Shankar et al., 2017) . In the present study, the severity of CIOM was associated with an increased difficulty in eating. However, this was not a serious enough CIOM-induced pain to interfere with sleep. This is consistent with reports from previous studies in which the severity of oral mucositis in cancer patients was 40.3% for WHO Grade 1 (Shankar et al., 2017) .
In the present study, the most prevalent site of CIOM was the ventral tongue, followed by the buccal mucosa, soft palate, and gingiva in patients with acute leukemia. Additionally, as the number of oral lesions increased, the severity of CIOM also increased. According to Woo et al., majority of ulcers in bone marrow transplant recipients occurred on movable nonkeratinized mucosa are found on buccal mucosa and soft palate (Woo, Sonis, & Sonis, 1990) . However, the usual sites of reactivation of intraoral HSV are nonmovable, keratinized mucosae found on the dorsum of the tongue, hard palate, and attached gingiva (Woo et al., 1990) . We did not investigate the relationship between HSV reactivation and CIOM, but HSV has been implicated in bone marrow transplant recipients as a crucial etiologic factor in the development of ulcerative mucositis (de Mendonca et al., 2012) . Oral manifestations may occur in any of the subtypes of leukemia, but they are known to occur commonly in AML than in ALL (Barrett, 1986) . Gingival infiltration of leukemic cells as one of the oral manifestations of AML has been reported in several studies (Fatahzadeh & Krakow, 2008; Lim & Kim, 2014; Wu, Fantasia, & Kaplan, 2002) . However, in our study, the CIOM of the gingiva was not present in AML patients and was found in only one case of ALL patients. According to a recent study on oral mucositis in pediatric ALL patients, lip mucosa was the most frequently affected site, with the gingiva being a relatively uncommon site (Ribeiro, Limeira, Dias de Castro, & Ferreti Bonan, 2017) . ALL is the most common and the most serious type of childhood cancer, accounting for about 80% of cases of leukemia between 0 and 19 years of age, and the prognosis for ALL is worse in adults over 30 years (Trencsenyi, Bako, Nagy, Kertai, & Banfalvi, 2015) . Therefore, only a few prospective studies have analyzed the intraoral findings in adult ALL patients, and further studies are needed to support our results.
This study has some limitations that have to be pointed out. To compare the clinical characteristics of AML and ALL, a relatively small number of participants, especially in ALL, were enrolled. Thus, a detailed and accurate comparison of clinical symptoms between AML and ALL was limited. Additionally, the follow-up period was limited, and this study does not allow us to draw a concrete conclusion about changes in CIOM over time. However, this study is strong in its prospective nature. It is noteworthy that our results firstly investigated the clinical characteristics of CIOM in adult patients with acute leukemia receiving intensive chemotherapy and/or HSCT. We also investigated how each clinical factor affects the severity of CIOM. These clinical features and relationships were compared between AML and ALL.
CIOM is very debilitating and a painful condition for adult patients with acute leukemia undergoing chemotherapy and a combination therapy with HSCT. CIOM in the buccal mucosa, ventral tongue, and soft palate was associated with an increase in CIOM severity. Impaired eating function was associated with the increased severity of CIOM. Dentists, physicians, and oral health practitioners should be familiar with the oral manifestations as well as the systemic complications of acute leukemia with intensive chemotherapy. With this, we hope that timely management for reducing the CIOM severity and improvement of the patients' quality of life can be provided. 
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